Operates diagnostic centres and laboratories offering pathology and imaging services, including SPECT and SPECT-CT scans, with facilities in Delhi and Gurugram. Revenue of Rs 83.11 crore in FY26 grew 6.6% from FY25, though profit after tax declined to Rs 525.33 Lacs from Rs 900.79 Lacs. The company listed on the BSE SME platform in January 2026 after raising Rs 36.89 crore through an IPO, with proceeds primarily intended for medical equipment purchases and working capital. In March 2026, it upgraded imaging equipment at its Gurugram Sector-40 centre from SPECT to SPECT-CT, and is revising the location for a new laboratory within Delhi. Employee costs account for 27.6% of revenue and other operating expenses for 31.2%. Total assets reached Rs 118.60 crore by FY26 year-end, nearly double the prior year, supported by IPO proceeds and increased borrowings. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Diagnostic services. Service-driven diagnostic business, asset-heavy in medical imaging equipment with capex of 27.2% of revenue
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 83 |
| EBITDA (ex other income) | — |
| margin % | — |
| Owners' profit | — |
| EPS, as reported (₹) | 3.48 |
| ROE % · ROCE % | — · 11.2 |
| Debt / equity (x) | — |
| Cash from operations | 4 |
| Capex | (23) |
| ₹ crore | Q4 FY26 |
|---|---|
| Revenue | 40 |
| Profit before tax | 1 |
| Net profit | — |
| EPS (₹) | 1.38 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DR. LAL PATH LABS LTD. | 31,794 | 45.7 | 12.51 | 37.0 | 20.1 | 24.8 | 11.8 | 35.0 |
| VIJAYA DIAGNOSTIC CEN LTD | 15,456 | 82.4 | 16.15 | 43.1 | 18.1 | 16.8 | — | 46.4 |
| METROPOLIS HEALTHCARE LTD | 12,088 | 25.0 | 7.93 | 28.9 | 12.5 | 14.4 | 10.5 | 25.8 |
| THYROCARE TECH LTD | 8,797 | 32.3 | 15.01 | 32.1 | 27.8 | 33.2 | 10.9 | 33.9 |
| NEPHROCARE HEALTH SERV L | 7,678 | 79.3 | 6.88 | 30.4 | 6.9 | 8.6 | — | 25.3 |
| KRSNAA DIAGNOSTICS LTD | 1,794 | 18.4 | 1.83 | 9.0 | 10.3 | 8.4 | — | 27.7 |
| SURAKSHA DIAGNOSTIC LTD | 1,693 | 47.2 | 6.95 | 17.2 | 12.9 | 11.5 | — | 36.0 |
| 3B BLACKBIO DX LTD. | 1,217 | 20.3 | 3.67 | 14.3 | 18.1 | 22.5 | (8.9) | 52.6 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 6 Sept 2026 · AGM notice dispatched and published in newspapers | compliance | minimal | — | — |
| 5 Sept 2026 · 14th AGM notice and FY26 annual report filed; key results shared | board shareholder meetings | low | — | — |
| 5 Sept 2026 · 14th AGM on 30 Sep 2026; book closure 23-30 Sep; e-voting 27-29 Sep | board shareholder meetings | low | — | — |
| 5 Sept 2026 · 14th AGM on Sep 30, 2026; Book Closure Sep 23-30 | board shareholder meetings | low | — | — |
| 5 Sept 2026 · 14th AGM on 30 Sept 2026; book closure from 23 Sept to 30 Sept | board shareholder meetings | low | — | — |
| 3 Sept 2026 · 14th AGM on Sep 30, 2026; book closure Sep 24-30 | board shareholder meetings | low | — | — |
| 3 Sept 2026 · 14th AGM on 30 Sep 2026; Book Closure 24-30 Sep | board shareholder meetings | low | — | — |
| 3 Sept 2026 · 14th AGM on 30 Sep 2026; book closure from 24 to 30 Sep | board shareholder meetings | low | — | — |
| 3 Sept 2026 · Board appoints Scrutinizer for 14th AGM e-voting process | compliance | low | — | — |
| 3 Sept 2026 · Board approves AGM notice, auditor re-appointment, terminates Jaipur lab deal | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 55.1 | 23.2 | 22 of 29 | 25% |
| ROCE | 8.0 | 6.1 | 13 of 29 | 57% |
| Market cap | 115 | 38 | 13 of 30 | 59% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
